FDA Approves IDP-126 (Cabtreo), First Triple-Combination Drug for Acne

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.

Related Keywords

California ,United States ,San Diego ,New York ,American ,Kunzmannk Hilary Baldwin ,Lawrence Eichenfield ,Hilary Baldwin ,Juliec Harper ,Acne Treatment Research Center ,Bausch Health ,Drug Administration ,Bausch Health Companies Inc ,American Academy Of Dermatology ,Dermatology Skin Care Center ,San Diego School Of Medicine ,University Of California ,Ortho Dermatologics ,Skin Care Center ,New Drug Application ,Global Severity Score ,American Academy ,New Orleans ,San Diego School ,Editorial Advisory Board ,Acne Treatment ,Research Center ,Maui Derm ,Colorado Springs ,Bausch Health Companies ,Combination Topical Treatment Effective ,Published March ,Change Acne ,Published June ,